A US retrospective cohort study found no association between angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) use and COVID-19 test positivity. The study included 18 472 patients tested for COVID-19 (mean age 49 years, 40% male, and 69% white), 12.4% were taking either ACEIs or ARBs. A positive COVID-19 test result was observed in 9.4% of patients. Among patients who tested positive, 24.3% were admitted to the hospital, 9.3% were admitted to an intensive care unit, and 6.4% required mechanical ventilation. Overlap propensity score weighting showed no significant association of ACEI and/or ARB use with COVID-19 test positivity. These data support various society guidelines to continue current treatment of chronic disease conditions with either ACEI or ARB during the COVID-19 pandemic. Source: https://jamanetwork.com/
Alcohol consumption was independently associated with a substantially higher risk of hepatocellular carcinoma (HCC) among…
Consuming sweets and simple sugars during antibiotic treatment was associated with greater gut microbiome disruption,…
A systematic review of 82 studies found that stroke related to cancer-associated coagulopathy (CAC) is…
Higher consumption of ultra-processed foods (UPFs) was associated with increased risks of multiple chronic diseases…
A meta-analysis of 15 randomized controlled trials involving 4,824 patients with high blood pressure found…
Higher levels of chronic systemic inflammation were associated with smaller left ventricular volumes, compensatory increases…
This website uses cookies.